Aloxi OK'd for post-op emesis

March 6, 2008

Palonosetron approved by FDA for postoperative nausea and vomiting.

Palonosetron (new indication. The 5-HT3 receptor antagonist can now be used for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. In a Phase III study involving 574 patients undergoing elective gynecologic or abdominal laparoscopic surgery, palonosetron achieved the co-primary endpoint of complete response—no vomiting or use of rescue medication for the first 24 hours after surgery. Palonosetron has been available since 2003 and is also approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and severely emetogenic chemotherapy.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.